

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTQ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	10/540,447
Filing Date	06/22/2005
First Named Inventor	Frans Eduard Janssens
Group Art Unit	1624
Examiner Name	E. Bernhardt
Attorney Docket Number	I.B.1731USPCT1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		EP	0532456					
		WO	04/033428					

Examiner Signature	Date Considered
-----------------------	--------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

⁴Unique citation designation number; ⁵See attached Kinds of U.S. Patent Documents; ⁶Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3); ⁷For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document; ⁸Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible; ⁹Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.B./

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	10/540,447
Filing Date	06/22/2005
First Named Inventor	Frans Eduard Janssens
Group Art Unit	1624
Examiner Name	E. Bernhardt
Attorney Docket Number	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Aguiar et al., <i>Physiol. & Behav.</i> 60:1183-1186 (1996)	
		Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC), <i>Annals of Oncol.</i> 9: 811-819 (1998)	
		Ballard et al., Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist, <i>European Journal of Pharmacology</i> (2001), 412(3), pgs. 255-264	
		Bertrand et al., <i>Trends Pharmacol. Sci.</i> 17:255-259 (1996)	
		Brodin et al., <i>Neuropeptides</i> 26:253-260 (1994)	
		Campos et al., <i>J. Clin. Oncol.</i> 19:1759-1767 (2001)	
		Cocquyt et al., <i>Eur. J. Cancer</i> 37:835-842 (2001)	
		Culman et al., <i>Can. J. Physiol. Pharmacol.</i> 73:885-891 (1995)	
		De Mulder et al., <i>Annals of Internal Medicine</i> , 113:834-840 (1990)	
		Duffy, R. A., Expert Opin. Emerg. Drugs (2004), 9 (1), pgs. 9-21	
		Elliott, P. J., <i>Exp. Brain. Res.</i> 73:354-356 (1988)	
		Giardina, G. et al., <i>Exp. Opin. Ther. Patents</i> , 10(6): 939-960 (2000)	
		Hesketh et al., <i>Clin. Oncol.</i> 17:338-343 (1999)	
		Hesketh et al., <i>J. Clin. Oncol.</i> 15:103-109 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/540,447
Filing Date	06/22/2005
First Named Inventor	Frans Eduard Janssens
Group Art Unit	1624
Examiner Name	E. Bernhardt
Attorney Docket Number	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Kramer et al., <i>Science</i> 281:1640-1645 (1998)	
		Krase et al., <i>Behav. Brain. Res.</i> 63:81-88 (1994)	
		Kris et al., <i>J. Clin. Oncol.</i> , 3:1379-1384 (1985)	
		Lejeune et al., The selective neurokinin (NK)1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study, <i>Brain Research</i> (2002), 935, pgs. 134-139	
		Longmore et al., <i>DN&P</i> 8(1):5-23 (1995)	
		Lundberg, J., <i>Can. J. Physiol. Pharmacol.</i> 73:908-914 (1995)	
		Maggi and Schwartz, <i>Trends Pharmacol. Sci.</i> 18: 351-355 (1997)	
		Maggi, C. A., <i>Gen. Pharmacol.</i> 26:911-944 (1995)	
		Mattson et al., <i>J. Org. Chem.</i> , 1990, 55, 2552-2554	
		Megens et al., <i>J. Pharmacol. Exp. Ther.</i> 302:696-709 (2002)	
		Meltzer et al., Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder, <i>The American Journal of Psychiatry</i> (2004), 161(6), pgs. 975-984	
		Navari et al., <i>N. Engl. J. Med.</i> 340:190-195 (1999)	
		Naylor et al., <i>Cancer. Surv.</i> 21:117-135 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

<i>Application Number</i>	10/540,447
<i>Filing Date</i>	06/22/2005
<i>First Named Inventor</i>	Frans Eduard Janssens
<i>Group Art Unit</i>	1624
<i>Examiner Name</i>	E. Bernhardt
<i>Attorney Docket Number</i>	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Okano et al., <i>J. Pharmacol. Exp. Ther.</i> 298:559-564 (2001)	
		Piedimonte et al., <i>J. Pharmacol. Exp. Ther.</i> 266:270-273 (1993)	
		Regoli et al., <i>Pharmacol. Rev.</i> 46(4):551-599 (1994)	
		Rein et al., <i>Symposia, S.01. New treatment strategies in schizophrenia, S.01.01 Antipsychotic effect of four different compounds - results of the metatrial, European Neuropsychopharmacology Volume 13, Supplement 4, October 2003, Page S95</i>	
		Rudd et al., <i>Neuropharmacology</i> 33:1607-1608 (1994)	
		Rudd et al., <i>Br. J. Pharmacol.</i> 119:931-936 (1996)	
		Rupniak et al., <i>Trends Pharmacol. Sci.</i> 20:485-490 (1999)	
		Sam et al., <i>Eur. J. Pharmacol.</i> 417:231-237 (2001)	
		Shirayama et al., <i>Brain. Res.</i> 739:70-78 (1996)	
		Stella, V. J. et al., "Prodrugs", <i>Drug Delivery Systems</i> , 1985, pp. 142-176 147-176	
		Stella et al., <i>Drugs</i> , 29, pp. 455-473 (1985)	
		Tattersall et al., <i>Neuropharmacology</i> 35:1121-1129 (1996)	
		Tattersall et al., <i>Neuropharmacology</i> 39:652-663 (2000)	
		Teixeira et al., <i>Eur. J. Pharmacol.</i> 311:7-14 (1996)	
		Tonini et al., <i>Gastroenterol.</i> 120:938-945 (2001)	
		Watson et al., <i>Br. J. Pharmacol.</i> 115:84-94 (1995)	

Examiner Signature	/Emily Bernhardt/	Date Considered	10/22/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.